ACRV Acrivon Therapeutics, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ACRV — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
76
List Date
2022-11-15
CIK
0001781174
Next Earnings
2026-11-12
EPS Forecast
($0.45) (3 est.)
Headquarters
Watertown, MA
Homepage
https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inh…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan--40.02%-27.15%6.68%-27.24%-1.92%
Feb--23.90%25.91%-4.67%-16.57%7.14%
Mar---38.49%25.44%-60.51%-9.15%-20.68%
Apr--3.88%25.38%-16.67%26.71%9.82%
May---5.15%-6.20%-21.05%-23.44%-13.96%
Jun--4.35%-24.68%7.21%14.10%0.24%
Jul---5.40%43.00%4.07%-13.79%6.97%
Aug---5.94%21.51%6.35%33.97%13.97%
Sep---18.36%-16.86%35.07%-0.97%-0.28%
Oct---41.78%14.61%9.94%-14.43%*-7.92%
Nov-22.78%-20.28%-5.37%1.29%---11.79%
Dec-7.84%11.56%-19.09%-0.41%---3.94%
Total-28.83%-58.73%29.20%-53.04%-40.26%-30.33%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.85
SMA 50: $1.97
SMA 200: $1.77
Current: $1.72
EMA 12: $1.78
EMA 26: $1.84
MACD: -0.0645 | Signal: -0.0077
BEARISH
ADX (14): 20.75
WEAK TREND
+DI: 15.21
−DI: 24.73

Momentum Oscillators

RSI (14): 41.16
NEUTRAL
Stoch %K: 26.66
Stoch %D: 31.57
Williams %R: -72.31

Volume & Volatility

BB Upper: $2.09
BB Lower: $1.60
NEUTRAL
OBV: 8,951,271
Vol SMA 20: 221,354
Vol ROC: 84.19%
ATR: $0.12
True Range: $0.08
HV 20: 54.9%
HV 30: 69.5%
HV 60: 70.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is the comprehensive stock analysis report for ACRV:

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6)

Key Drivers and Primary Risks:

  • Trend indicators suggest a mixed signal, with short-term momentum pointing to a potential uptrend while medium-term momentum is neutral.
  • RSI reading of 52.68 indicates a neutral market condition.
  • Beta of 1.77 indicates high volatility relative to the broader market.

2-3 Sentence Investment Thesis: ACRV's recent price action is characterized by a mix of positive and negative signals, making it a neutral investment at this time. While there are some attractive technical levels and potential catalysts on the horizon, the stock's high volatility and mixed momentum pose significant risks to investors. As such, we recommend a cautious approach, focusing on risk management and waiting for clearer signals before taking a position.

Recent News Sentiment Impact: None (No recent news available)

Technical Analysis

Trend Direction:

  • Short-term: Neutral
  • Medium-term: Neutral
  • Long-term: Bearish

Support/Resistance Levels:

Support: $2.14, $1.84 Resistance: $2.40, $2.65

Momentum Signals:

RSI (14): 52.68 (neutral) MACD: Bullish signal line crossover Bollinger Bands: Neutral signal

Volume Analysis:

Volume SMA 20: 455138.70 On-Balance Volume (OBV): 42756197.00 Volume Rate of Change: -76.48%

News & Sentiment Analysis

Recent Headlines Summary: No recent news available

Sentiment Assessment: Neutral (No news sentiment data)

Catalyst Identification: None (No earnings or regulatory catalysts announced)

Market Narrative: The lack of recent news and mixed technical signals creates a neutral market narrative.

Risk & Volatility Assessment

Beta Interpretation:**

Beta of 1.77 indicates high risk relative to the broader market.

Volatility Regime:**

Current volatility is higher than historical levels, posing risks for investors.

Options Market Signals:** None (No options data available)

Downside Protection: Support levels at $2.14 and $1.84

Market Context & Positioning

Sector Performance: Neutral (ACRV's sector is mixed)

Institutional Activity: No notable institutional activity

Correlation Analysis: Correlation with market: 0.30, indicating a relatively low correlation

Relative Valuation: ACRV is trading within its recent range

Key Levels & Action Items

Critical Price Levels: Support: $2.14, $1.84 Resistance: $2.40, $2.65

Breakout/Breakdown Levels: None (No immediate support or resistance levels)

Time-Sensitive Catalysts: Earnings date: 2025-08-13

Risk Management: Consider stop-loss levels at $2.10 and $1.90, with position sizing considerations based on risk tolerance.

Note that the analysis is neutral due to mixed technical signals and the lack of recent news. The high volatility and beta pose significant risks for investors, making it essential to manage risk effectively.

Generated
News
All ACRV news →
Showing 1–10 of 50
Page 1 of 5

ACRV Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 2.0234
Alpha: -4.68%
Correlation: 0.2893
R-Squared: 8.4%
Stock Volatility: 89.1%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ACRV
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$1.4M
0.00%
#2170 of 3138+0.1%13F
Citadel Hedge fund
Ken Griffin
$73K
0.00%
#5893 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ACRV Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

47 filers22,101,414 shares$39.78M value
# Filer Shares Value % of Total % of Float Period
1 RA CAPITAL MANAGEMENT, L.P. 12,229,396 $21.77M 54.72% — 2026-06-30
2 Sands Capital Alternatives, LLC 2,289,271 $4.07M 10.24% — 2026-06-30
3 ACADIAN ASSET MANAGEMENT LLC 1,165,119 $2.07M 5.21% — 2026-06-30
4 Vanguard Capital Management LLC 952,008 $1.69M 4.26% — 2026-06-30
5 Vanguard Group Inc Custodian 698,857 $1.68M 4.23% — 2025-12-31
6 Wellington Management Group LLP Custodian 888,130 $1.58M 3.97% — 2026-06-30
7 RENAISSANCE TECHNOLOGIES LLC 758,863 $1.35M 3.40% — 2026-06-30
8 Two Sigma Investments, LP Custodian 641,498 $1.14M 2.87% — 2026-06-30
9 Marshall Wace, LLP Custodian 531,856 $946.70K 2.38% — 2026-06-30
10 BRIDGEWAY CAPITAL MANAGEMENT, LLC 378,900 $674.44K 1.70% — 2026-06-30
11 Geode Capital Management, LLC Custodian 265,241 $472.27K 1.19% — 2026-06-30
12 BlackRock, Inc. Custodian 239,112 $425.62K 1.07% — 2026-06-30
13 GSA CAPITAL PARTNERS LLP 200,415 $357.00K 0.90% — 2026-06-30
14 Vanguard Fiduciary Trust Co 184,128 $327.75K 0.82% — 2026-06-30
15 XTX Topco Ltd 178,239 $317.26K 0.80% — 2026-06-30
16 Jane Street Group, LLC Custodian 74,648 $132.87K 0.33% — 2026-06-30
17 Northern Trust Corp Custodian 67,202 $119.62K 0.30% — 2026-06-30
18 State Street Corp 67,145 $119.52K 0.30% — 2026-06-30
19 UBS Group AG Custodian 43,850 $78.05K 0.20% — 2026-06-30
20 Citadel Advisors LLC Custodian 41,276 $73.47K 0.18% — 2026-06-30
21 Dimensional Fund Advisors LP Custodian 29,332 $52.21K 0.13% — 2026-06-30
22 Spark Investment Management LLC 28,300 $50.37K 0.13% — 2026-06-30
23 PRELUDE CAPITAL MANAGEMENT, LLC 24,015 $42.75K 0.11% — 2026-06-30
24 Bank of America Corp Custodian 16,407 $29.20K 0.07% — 2026-06-30
25 Verdad Advisers, LP 15,054 $26.80K 0.07% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

ACRV Insider Trading (Form 4)

Latest: 2026-10-07
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-07 Mary Miller Chief Legal Officer Sell (S) −294 $1.99 -$585 EDGAR
2026-09-02 Michaela Levin Chief Business Officer Award (A) +30,000 — EDGAR
2026-08-27 Kristina Masson EVP - Business Operations Sell (S) −28,072 $2.21 -$61.9K EDGAR
2026-08-20 Eric Devroe Chief Operating Officer Sell (S) −604 $2.01 -$1.2K EDGAR
2026-08-20 Katharine Peterson Chief Accounting Officer Sell (S) −101 $2.01 -$203 EDGAR
2026-08-20 Mary Miller Chief Legal Officer Sell (S) −185 $2.01 -$372 EDGAR
2026-08-20 Kristina Masson EVP - Business Operations Sell (S) −3,426 $2.01 -$6.9K EDGAR
2026-08-20 Erick Gamelin Chief Development Officer Sell (S) −400 $2.01 -$804 EDGAR
2026-08-06 Adam D. Levy Chief Financial Officer Sell (S) −1,142 $1.57 -$1.8K EDGAR
2026-08-06 Adam D. Levy Chief Financial Officer Sell (S) −1,142 $1.57 -$1.8K EDGAR
2026-07-23 Mary Miller Chief Legal Officer Sell (S) −573 $1.76 -$1.0K EDGAR
2026-06-22 Charles M Baum Director Grant (A) +20,275 opt — EDGAR
2026-06-22 Sharon Shacham Director Grant (A) +20,275 opt — EDGAR
2026-06-22 Derek DiRocco Director Grant (A) +20,275 opt — EDGAR
2026-06-22 Santhosh Palani Director Grant (A) +20,275 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ACRV Insider Holdings

19 insiders · @ $1.72
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Joseph Edelman 10%+ Owner 3,104,139 $5.34M $48.71M 3 2025-05-01
2 Peter Blume-Jensen President and CEO 2,631,660 $4.53M $164.2K 18 2026-05-26
3 Kristina Masson EVP - Business Operations 2,615,911 $4.50M -$68.8K 16 2026-08-27
4 RA Capital Healthcare Fund LP Director 426,302 $733.2K $0 2 2026-04-23
5 Eric Devroe Chief Operating Officer 146,349 $251.7K $16.0K 20 2026-08-20
6 Mary Miller Chief Legal Officer 81,715 $140.5K -$2.0K 33 2026-10-07
7 Adam D. Levy Chief Financial Officer 66,008 $113.5K $11.4K 7 2026-08-06
8 Erick Gamelin Chief Development Officer 52,592 $90.5K -$804 17 2026-08-20
9 Mansoor Raza Mirza Chief Medical Officer 38,817 $66.8K $0 3 2026-05-20
10 Michaela Levin Chief Business Officer 30,000 $51.6K $0 1 2026-09-02
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ACRV Board & Officers

As of SEC filings through Oct 26, 2026

Directors 13

Officers 9

10% owners 4

Changes in the last 10 years (45)
Aug 31, 2026Michaela Levin became Chief Business Officer
May 1, 2025Perceptive Life Sciences Master Fund Ltd reported in an SEC filing no longer being a 10% owner
May 1, 2025Perceptive Advisors LLC reported in an SEC filing no longer being a 10% owner
May 1, 2025Joseph Edelman reported in an SEC filing no longer being a 10% owner
Apr 9, 2025Mansoor Raza Mirza became Chief Medical Officer
Apr 1, 2025Adam D. Levy became Chief Financial Officer
Mar 11, 2025The company announced the departure of Rasmus Holm-Jorgensen as Chief Financial Officer in an SEC filing
Jun 24, 2024RA Capital Nexus Fund II, L.P. no longer listed as a 10% owner in SEC filings
May 13, 2024Katharine Peterson became Chief Accounting Officer
Mar 4, 2024Santhosh Palani became a director
Feb 16, 2024Erick Gamelin listed as Chief Development Officer (previously Chief Medical Officer) in SEC filings
Feb 8, 2024Ivana Magovcevic-Liebisch became a director
Jan 2, 2024Jean-Marie Cuillerot became Chief Medical Officer
Sep 26, 2023Mary Miller became Chief Legal Officer
Jun 22, 2023Charles M Baum became a director
Nov 21, 2022Wellington Biomedical Innovation Master Investors (Cayman) I L.P. reported in an SEC filing no longer being a 10% owner
Nov 17, 2022Perceptive Life Sciences Master Fund Ltd became a 10% owner
Nov 17, 2022Perceptive Advisors LLC became a 10% owner
Nov 17, 2022Joseph Edelman became a 10% owner
Nov 9, 2022Wiaczeslaw Smolokowski became a 10% owner
Not reported recently (6)
  • Jean-Marie Cuillerot · Last reported as Chief Medical Officer in an SEC filing dated Mar 4, 2025
  • Andreas Hadjimichael · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
  • Chione Ltd · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
  • Marcin Czernik · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
  • Wiaczeslaw Smolokowski · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
  • Anastasis Nikolaou · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ACRV Proposed Insider Sales (Form 144)

Latest: 2026-08-25
Last 30d: 0 filings  ·  Last 90d: 1 filing · $31K notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Peter Blume-Jensen (1, $31K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-25 Peter Blume-Jensen Officer, Director 14,036 $30.6K 2026-08-25 Morgan Stanley Smith Barney LLC — EDGAR
2023-06-12 Chione Ltd 10% Stockholder 219,259 $2.73M 2023-06-12 Merrill — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
4 ETFs hold ACRV
4 shown · $2.34M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $1.4M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $780,212 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $103,622 $1.2B 2026-10-23
4 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $12,210 — 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.